What are different antibody drug conjugates?

Antibody-Drug Conjugates (ADCs) are a new class of highly potent biological drugs built by attaching a small molecule anticancer drug or another therapeutic agent to an antibody, with either a permanent or a labile linker. The antibody targets a specific antigen only found on target cells.

What is the name of the conjugates in cancer treatment?

Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs.

What is ADC in drug discovery?

Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity.

What are ADC linkers?

The linker connects the antibody and the cytotoxic payload and is a key component in the function of ADCs. The linker imparts the following characteristics to ADCs: (1) high stability in the circulation, and (2) specific release of payload in the target tissue.

Are antibody drug conjugates considered immunotherapy?

Antibody drug conjugates (ADCs) are a form of targeted immunotherapy. They are composed of three components: a monoclonal antibody (mAb) and a cytotoxic payload made from a chemotherapy agent, which are connected together using a chemical linker.

Are antibody drug conjugates combination products?

drug conjugates (ADCs) are therapeutic products that include a monoclonal antibody conjugated to a drug. ADCs are thus a combination of two separate classes of products regulated by the United States Food & Drug Administration: a biologic and a drug.

What is ADC development?

Today’s ADCs use humanized antibodies, highly cytotoxic organic payloads, and linkers designed to retain the cell-killing agent until the ADC has found its target then, after the cell internalizes the ADC through surface receptors, facilitates payload release into the cell. …

Are ADCs immunotherapy?

How are antibody drug conjugates administered?

Antibodies are directed to a large variety of antigens overexpressed on tumor cells, tumor vasculature, or tumor-supporting stroma. After internalization, the ADC is transferred to lysosomes where the cytotoxic component is released, finally killing the target cell. All ADCs are administered via intravenous injection.

What makes a good ADC target?

Ideal targets of ADCs are antigen expressed exclusively on the surface of tumor cells. Lineage-specific antigens expressed by hematological malignancies have been thereby extensively explored as perfect candidates with many specific ADCs already approved and other under development [3].